Septic shock in the era of precision medicine: rethinking fluids, vasopressors, and immunomodulation

Septic shock remains a high-mortality syndrome despite advances in early recognition, antimicrobial therapy, source control, and protocolized resuscitation. A major limitation of current practice is that septic shock is often managed as a single clinical entity, whereas patients meeting the same diagnostic criteria may differ substantially in hemodynamic phenotype, endothelial injury, microcirculatory function, immune state, coagulation activation, fluid tolerance, and vasopressor responsiveness. These differences help explain why biologically plausible therapies frequently fail when tested in unselected populations. This narrative review synthesizes evidence supporting a precision-oriented approach to septic shock across three therapeutic domains—fluid therapy, vasopressor support, and immunomodulation—supported by two cross-cutting precision layers: biological phenotyping and bedside precision tools. We distinguish bedside clinical phenotypes from biological endotypes and explain how this framework can refine resuscitation decisions. Fluid therapy is reframed as a titrated intervention requiring assessment of both fluid responsiveness and fluid tolerance. Vasopressor therapy is discussed beyond a uniform mean arterial pressure target, with emphasis on timing, agent selection, tissue perfusion, and individualized weaning. Immune, endothelial, and coagulation phenotyping are presented as biological bridges between bedside physiology and targeted therapy, while immunomodulation is considered a promising but still investigational frontier requiring patient stratification. Finally, we propose a pragmatic precision-resuscitation framework that integrates lactate kinetics, capillary refill time, point-of-care ultrasound, congestion assessment, and immune/endothelial biomarkers where available. Precision care should not delay time-critical sepsis interventions; rather, it should mature protocolized management into a dynamic process of early treatment, repeated reassessment, and phenotype-directed adjustment.